Dexamethasone study shows promising results for treating COVID-19 patients
The New England Journal of Medicine last week released a study showing that the use of dexamethasone resulted in a lower, 28-day mortality rate among patients receiving invasive ventilation or oxygen.
The study indicated lower incidence of death among 2,104 patients treated with dexamethasone, compared to 4,321 patients receiving usual care. However, results showed very little impact in patients not receiving respiratory support.
The Food and Drug Administration also recently updated its COVID-19 treatment guidelines for corticosteroids, including dexamethasone. FDA said such drugs can be used for up to 10 days in patients requiring supplemental oxygen, but not with those who are mechanically ventilated or do not require supplemental oxygen.
Related News Articles
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…